Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]
Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods.
Induced Pluripotent Stem Cells | Shinya Yamanka
Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells.
Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.
Stem cell market intelligence is defined as data relevant to the stem cell industry, gathered for the purpose of making informed business decisions. Business activities that market intelligence may support include:
- New product development
- Sales strategy
- Market strategy
- New client acquisition
iPS cell research is on the rise, as clinical applications for the iPSC-derived tissues increase in number. Induced pluripotent stem cells (iPS cells) are a type of pluripotent stem cell that can be generated directly from adult cells. There are now two iPSC-derived cell therapeutic products in clinical trials, RIKEN’s iPSC-derived retinal sheets for age-related macular degeneration (AMD) and Cynata Therapeutics’ CYP-001 for graft vs. host disease (GvHD).
Kyoto University is also launching the world’s first clinical trial utilizing an iPSC-derived therapeutics for Parkinson’s disease.
iPS Cell Research
With both iPS cell research and clinical activity expanding, the market for iPSC-derived tissues is poised to experience rapid growth.
With more than 200 different cell types in the human body, a key goal of Cellular Dynamics International (CDI), a Fujifilm company, is to continue to expand the portfolio of available human iPSC-derived tissues where possible and where there is a scientific need. For example, CDI’s first-generation GABAergic iCell Neurons are inhibitory cortical neurons that recapitulate many features of human neurons.
The utility of this cell type was immediately demonstrated as an alternative model to primary animal-based neuronal preparations for assessing neurite outgrowth as well as developmental and general neuronal cytotoxicity. However, as they are a primarily inhibitory neuronal population, they provided limited utility for assessing networked neuronal electrical activity. [Read more…]
Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.
Existing iPS Cell Trials
This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]